Cellceutix Drug Slows Tumor Growth by 100% in Head and Neck Cancer

Cellceutix Corporation (CTIX)

Cellceutix Corporation (CTIX)

Cellceutix Corporation (OTCQB: CTIX),a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, recently provided additional research data on Kevetrin™, its p53 breakthrough anti-cancer compound.

Kevetrin™ was studied as combination therapy with radiation to treat human head and neck cancer lines implanted in animals. While tumors treated with Kevetrin™ or radiation alone each showed significant anti-tumor activity, tumors treated with Kevetrin™ followed by radiation one week later demonstrated superior results in controlling tumor size. Since the sequence of Kevetrin™ followed by radiation outpaced the reverse (radiation then Kevetrin™), Kevetrin™ may be acting as a “radiosensitizer,” a term used to describe sensitization of tumor cells to radiation at the cellular level. Further information on the study is available at

Dr. Krishna Menon, Chief Scientific Officer of Cellceutix, commented, “Our research to date has shown the potential of Kevetrin™ as a stand-alone therapy. This additional data demonstrates its value as a combination therapy. We believe the radiosensitizer capacity of Kevetrin™ is once again attributable to its interaction with p53. The data that we have collected in our pre-clinical studies on Kevetrin™ gives me great hope that Cellceutix is developing a drug that one day will have a major impact on cancer treatments.”

To provide investors with a greater understanding of Cellceutix, an audio interview has been conducted with The Green Baron Report. The webcast is available for listening or download at

Cellceutix Corporation (CTIX) Stock Quote and News:


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Apple and Hammacher Store Sales Should Boost AltiGen’s iFusion Revenue(0)

Sales of AltiGen Communications’ (OTCQX:ATGN) could be getting a shot in the arm for the remainder of this quarter and in upcoming quarters as their revolutionary iFusion SmartStation is now available at the Apple, Inc.’s (NASDAQ:AAPL) Apple Store ( and the uber-popular Hammacher Schlemmer website ( The iFusion SmartStation is a multi-function iPhone docking station

Bond Labs Diet, Workout and Health Products Fuel Bodies and Record Revenues(0)

Proprietary nutritional supplements provider Bond Laboratories, Inc. (OTCBB:BNLB) could be viewed as one of those small cap companies that is coiling like a spring and just waiting for the release point to catapult higher.  The Nebraska-based company has several irons in the fire, but operates primarily through its wholly-owned NDS Nutrition Products division, an outfit

Tapping Emerging Markets, Premier Power Inks New 5 MW Solar Project Deal(2)

Solar power plant developer Premier Power Renewable Energy, Inc. (OTCBB:PPRW) has signed a new supply agreement to provide a total of 5 MWp in equipment for solar projects located in Scandinavia. The plants will be funded through an agreement with a Danish firm Viasol A/S.  Shipments are slated to begin this month with completion of

iMetrik Poised for Machine-to-Machine Data to Become Next Internet Boom(0)

Investors that didn’t catch the New York Times article The Age of Big Data on February 11th or know anything about The Internet of Things should take a moment and check them out as they provide a window to the future of communications.  Companies such as International Business Machines (NYSE:IBM), RF Micro Devices (NASDAQ:RFMD) and

ecoTECH Energy Prepares for Site Construction of Eco-Industrial Complex in McBride, BC and Receives $55 Million Debt Financing(0)

In preparation for what will be one of the most advanced complexes of its type in North America, ecoTECH Energy Group, Inc. (OTCBB:ECTH) has begun to clear the McBride, British Columbia Lamming Mills site for its Aquaponics and Combined Heat and Power (CHP) facility that is slated for construction this Spring.  The Canadian Ministry of

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.